Mink Therapeutics Inc (INKT)

Jul 23, 2025

MiNK Therapeutics Inc. Stock Analysis and ForecastConsistent triple returns - Autocar Professional

Jul 23, 2025

Jul 23, 2025

What drives MiNK Therapeutics Inc. stock priceUnprecedented profits - jammulinksnews.com

Jul 23, 2025

Jul 22, 2025

What analysts say about MiNK Therapeutics Inc. stockBreakneck growth rates - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

Is MiNK Therapeutics Inc. a good long term investmentFree Investment Timing Strategies - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

(INKT) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

Jul 22, 2025

Jul 22, 2025

How MiNK Therapeutics Inc. stock performs during market volatilityRisk Managed Trading Strategy - Newser

Jul 22, 2025

Jul 21, 2025

MiNK Therapeutics (NASDAQ:INKT) Upgraded at B. Riley - Defense World

Jul 21, 2025

Jul 18, 2025

MiNK Therapeutics Announces Clinical Trial Success - MSN

Jul 18, 2025

Jul 17, 2025

MiNK Therapeutics Stock Surges on Breakthrough Testicular Cancer Remission and iNKT Cell Therapy Progress - Oncodaily

Jul 17, 2025

Jul 17, 2025

MiNK Therapeutics (NASDAQ:INKT) Rating Lowered to “Neutral” at HC Wainwright - Defense World

Jul 17, 2025

Jul 17, 2025

Mink Therapeutics Shares Slide After Announcing $50 Million Stock Offering - MSN

Jul 17, 2025

Jul 17, 2025

MiNK Therapeutics (NASDAQ:INKT) Cut to Neutral at HC Wainwright - Defense World

Jul 17, 2025

Jul 16, 2025

Mink Therapeutics stock tumbles on $50 million stock offering - Investing.com

Jul 16, 2025

Jul 15, 2025

Agenus unit, MiNK surges after peer-reviewed data for lead drug - MSN

Jul 15, 2025

Jul 15, 2025

What makes MiNK Therapeutics Inc. stock price move sharplyAI Powered Stock Call - Newser

Jul 15, 2025

Jul 15, 2025

Why MiNK Therapeutics Inc. stock attracts strong analyst attentionFree Access to Investment Community - Newser

Jul 15, 2025

Jul 15, 2025

MiNK Therapeutics stock rating downgraded to Neutral by H.C. Wainwright - Investing.com Canada

Jul 15, 2025

Jul 15, 2025

MiNK Therapeutics Plummets 29%—What’s Driving the Sell-Off? - AInvest

Jul 15, 2025

Jul 15, 2025

MiNK Therapeutics Plummets 28.59% — What’s Driving the Sell-Off? - AInvest

Jul 15, 2025

Jul 15, 2025

Mink Therapeutics stock tumbles on $50 million stock offering By Investing.com - Investing.com Nigeria

Jul 15, 2025

Jul 15, 2025

MiNK Therapeutics publishes research on CAR-iNKT cell therapy By Investing.com - Investing.com South Africa

Jul 15, 2025

Jul 15, 2025

MiNK Therapeutics enters $50 million at-the-market sales agreement with B. Riley Securities By Investing.com - Investing.com South Africa

Jul 15, 2025

Jul 15, 2025

MiNK Therapeutics enters $50 million at-the-market sales agreement with B. Riley Securities - Investing.com Canada

Jul 15, 2025

Jul 15, 2025

MiNK Therapeutics Publishes Peer-Reviewed Article Highlighting Innovations in CAR-iNKT Cell Therapies for Solid Tumors - Nasdaq

Jul 15, 2025

Jul 15, 2025

MiNK Therapeutics Announces Frontiers in Immunology - GlobeNewswire

Jul 15, 2025

Jul 15, 2025

MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy - TradingView

Jul 15, 2025

Jul 15, 2025

Revolutionary iNKT Cell Therapy Achieves 2-Year Complete Remission in Treatment-Resistant Cancer - Stock Titan

Jul 15, 2025

Jul 15, 2025

MiNK Therapeutics tumbles after $50 mln stock offering filing - TradingView

Jul 15, 2025

Jul 15, 2025

INKT’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com

Jul 15, 2025

Jul 15, 2025

MiNK Therapeutics Enters $50M Sales Agreement with B. Riley - TipRanks

Jul 15, 2025

Jul 15, 2025

MiNK Therapeutics Plunges 24.87% After William Blair Downgrade - AInvest

Jul 15, 2025

Jul 15, 2025

INKT sets up $50M ATM with B. Riley, adds financing flexibility | INKT SEC FilingForm 8-K - Stock Titan

Jul 15, 2025